JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on January 19, 2006; DOI: 10.1124/jpet.105.097667


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.105.097667v1
317/2/500    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lipecka, J.
Right arrow Articles by Davezac, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lipecka, J.
Right arrow Articles by Davezac, N.


Received for publication October 27, 2005.
Revised January 18, 2006.
Accepted for publication January 18, 2006.

Rescue of {Delta}F508-CFTR by curcumin: involvement of the keratin 18 network

Joanna Lipecka 1, Caroline Norez 2, Noura Bensalem 1, Maryvonne Baudoin-Legros 1, Gabrielle Planelles 1, Frederic Becq 2, Aleksander Edelman 1, Noelie Davezac 3*

1 INSERM U467 2 CNRS UMR 6187 3 Universite Paris XI

* Address correspondence to: E-mail: davezac{at}necker.fr

Abstract

The most common mutation in the CFTR gene, {Delta}F508, causes retention of {Delta}F508-CFTR in the endoplasmic reticulum and leads to the absence of CFTR Cl- channels in the plasma membrane. {Delta}F508-CFTR retains some Cl- channel activity so increased expression of {Delta}F508-CFTR in the plasma membrane can restore Cl- secretion deficiency. Recently, curcumin was shown to rescue {Delta}F508-CFTR localization and function. In our previous work, the keratin 18 network was implicated in {Delta}F508-CFTR trafficking. Here, we hypothesized that curcumin could restore a functional {Delta}F508-CFTR to the plasma membrane acting via the K18 network. First, we analyzed the effects of curcumin on the localization of {Delta}F508-CFTR in different cell lines (HeLa cells stably transfected with WT-CFTR or {Delta}F508-CFTR, CALU-3 cells or CF pancreatic epithelial cells CFPAC-1) and found it was significantly delocalized towards the plasma membrane in {Delta}F508-CFTR-expressing cells. We also performed a functional assay for the CFTR chloride channel in CFPAC-1 cells treated or not with curcumin and detected an increase in a cAMP-dependent chloride efflux in treated {Delta}F508-CFTR-expressing cells. Then, the K18 network was analyzed by immunocytochemistry and immunoblot exclusively in curcumin-treated or untreated CFPAC-1 cells because of their endogenic {Delta}F508-CFTR expression. After curcumin treatment, we observed a remodeling of the K18 network and a significant increase in K18 Ser52 phosphorylation, a site directly implicated in the reorganization of intermediate filaments. With these results, we propose K18 as a new therapeutic target and curcumin and/or its analogs might be considered as potential therapeutic agents for cystic fibrosis.


Key words: CFTR, Cystic Fibrosis, chloride secretion, curcumin, keratin 18, traffic


This article has been cited by other articles:


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
C. Norez, M. Pasetto, M. C. Dechecchi, E. Barison, C. Anselmi, A. Tamanini, F. Quiri, L. Cattel, P. Rizzotti, F. Dosio, et al.
Chemical conjugation of {Delta}F508-CFTR corrector deoxyspergualin to transporter human serum albumin enhances its ability to rescue Cl- channel functions
Am J Physiol Lung Cell Mol Physiol, August 1, 2008; 295(2): L336 - L347.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics.